Pfizer faces a lawsuit in which women allege the drugmaker failed to warn them about the risks of meningioma associated with ...
Commissioner Marty Makary on Monday denied recent reports suggesting plans for his agency to add a black box warning onto ...
Health and Me on MSN
Addyi: FDA approves libido-boosting drug for postmenopausal women – what does it mean for women’s sexual health?
The FDA has expanded approval of Addyi, a once-daily libido drug, allowing postmenopausal women over 65 to use it. The ...
An FDA panel of experts has called for a loosening of regulations and expanding access to testosterone replacement therapy.
“All Israeli medtech companies aim for the American market,” Hadari said. “At a certain stage in a company’s growth, it will ...
The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...
This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you ...
On Dec. 15, Sprout Pharmaceuticals received approval to use its pill, Addyi (flibanserin), to treat low sexual desire in ...
Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...
The declaration of fentanyl a weapon of mass destruction is the latest move by President Donald Trump casting the nation’s ...
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...
On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS or the “Agency”) released the 2027 Medicare Advantage and Part D Proposed Rule (the “Proposed Rule”).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback